Mylan has announced the U.S. Food and Drug Administration approval of Wixela Inhub (fluticasone propionate and salmetero...
Magnolia Medical Technologies has announced a $20 million Series C financing round to scale the company’s infrastr...
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced a worldwide collaboration and license agreem...
Eli Lilly and Companyhas announced that USFDA has granted approval for a new indication for ALIMTA® (pemetrexed...
I Holland, leaders in the manufacture of tablet tooling for the pharmaceutical and nutraceutical markets is pleased...
Spero Therapeutics, a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and ...
Aldeyra Therapeutics, a biotechnology company developing and commercializing next-generation medicines for immune-mediat...
Ireland based Medtronic has announced the first U.S. patients treated with the Mazor X Stealth(TM) Edition for spine sur...
Applied Health Signals company, Livongo Health has announced that it has signed a definitive agreement to acquire Denver...
Pfizer and Eli Lilly have announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg i...
Total spending on medicines is expected to top $1.5 trillion by 2023, up 50 percent from 2014, even as annual growth mod...
Ionis Pharma, Inc. the leader in antisense therapeutics, has announced that its partner Roche has enrolled the firs...
Thermo Fisher Scientific Inc., the world leader in serving science, has signed a definitive agreement to sell its Anatom...
Zimmer Biomet, a global leader in musculoskeletal healthcare has announced U.S. Food and Drug Administration 5...
By the end of 2019, up to 15 percent of the global healthcare spending is expected to be directed toward value-base...
A Phase 1 clinical trial of investigational vaccines intended to protect against Zaire ebolavirus (Ebola) is underway at...
VirTrial, a leading telehealth platform provider for virtual clinical trials, has named Amanda Rangel as VP of Business ...
Dicerna Pharmaceuticals, a leading developer of RNA interference (RNAi) therapeutics, today announced the dosing of the ...
